IL-23 Plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects

Immunological Investigations

Volumn 44, Issue 1, 2015, Pages 36-44

  Shajarian, Mansour ^a,c   Alsahebfosoul, Fereshteh ^b,c   Etemadifar, Masoud ^b,c   Sedaghat, Nahid ^b,c   Shahbazi, Mansoureh ^b,c   Firouzabadi, Fatemeh Pourgadegan ^b,c   Dezashibi, Hoda Mohammad ^b,c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Multiple Sclerosis and Neuroimmunology Research Center   (Iran)

Author keywords

ELISA; Interleukin 23 (IL 23); Multiple Sclerosis; Neuroinflammatory

Indexed keywords

INTERLEUKIN 23; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFANT; MALE; MULTIPLE SCLEROSIS; NEWBORN; PROTEIN BLOOD LEVEL; VENOUS BLOOD; BLOOD; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-23; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84918812009     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2014.930477     Document Type: Article

References (42)

1. Awasthi A, Riol-Blanco L, Jager A, et al. (2009). Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol, 182, 5904-8.
2. Bastos KR, de Deus Vieira de Moraes L, Zago CA, et al. (2005). Analysis of the activation profile of dendritic cells derived from the bone marrow of interleukin-12/interleukin-23-deficient mice. Immunology, 114, 499-506.
3. Beadling C, Slifka MK. (2006). Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch Immunol Ther Exp (Warsz), 54, 15-24.
4. Belladonna ML, Renauld JC, Bianchi R, et al. (2002). IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol, 168, 5448-54.
5. Bornsen L, Khademi M, Olsson T, et al. (2011). Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler, 17, 32-42.
6. Braitch M, Nunan R, Niepel G, et al. (2008). Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol, 65, 633-5.
7. Chen YC, Chen SD, Miao L, et al. (2012). Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol, 243, 56-60.
8. Chiocchetti A, Comi C, Indelicato M, et al. (2005). Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J Neuroimmunol, 163, 172-8.
9. Comabella M, Pericot I, Goertsches R, et al. (2005). Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol, 158, 231-9.
10. Compston A, Coles A. (2008). Multiple sclerosis. Lancet, 372, 1502-17.
11. Cua DJ, Sherlock J, Chen Y, et al. (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature, 421, 744-8.
12. Etemadifar M, Abtahi SH. (2012). Multiple sclerosis in Isfahan, Iran: Past, Present and Future. Int J Prev Med, 3, 301-2.
13. Etemadifar M, Abtahi SH, Akbari M, et al. (2014). Multiple sclerosis in Isfahan, Iran: An update. Mult Scler, 20, 1145-8.
14. Etemadifar M, Maghzi AH. (2011). Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult Scler, 17, 1022-7.
15. Etemadifar M, Sajjadi S, Nasr Z, et al. (2013). Epidemiology of multiple sclerosis in Iran: A systematic review. Eur Neurol, 70, 356-63.
16. Gerosa F, Baldani-Guerra B, Lyakh LA, et al. (2008). Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med, 205, 1447-61.
17. Ghoreschi K, Laurence A, Yang XP, et al. (2010). Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature, 467, 967-71.
18. Goldberg M, Nadiv N, Luknar-Gabor O, et al. (2009). Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblastlike synoviocytes. Mol Immunol, 46, 1854-9.
19. Gran B, Zhang GX, Yu S, et al. (2002). IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: Evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol, 169, 7104-10.
20. Iwakura Y, Ishigame H. (2006). The IL-23/IL-17 axis in inflammation. J Clin Invest, 116, 1218-22.
21. Kikly K, Liu L, Na S, Sedgwick JD. (2006). The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation. Curr Opin Immunol, 18, 670-5.
22. Kopp T, Lenz P, Bello-Fernandez C, et al. (2003). IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: Evidence for enhanced cutaneous immunity. J Immunol, 170, 5438-44.
23. Krakauer M, Sorensen P, Khademi M, et al. (2008). Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: Interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler, 14, 622-30.
24. Langrish CL, Chen Y, Blumenschein WM, et al. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med, 201, 233-40.
25. Langrish CL, McKenzie BS,Wilson NJ, et al. (2004). IL-12 and IL-23: Master regulators of innate and adaptive immunity. Immunol Rev, 202, 96-105.
26. Lankford CS, Frucht DM. (2003). A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol, 73, 49-56.
27. Liao JJ, Huang MC, Goetzl EJ. (2007). Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate. J Immunol, 178, 5425-8.
28. Lovett-Racke AE, Yang Y, Racke MK. (2011). Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta, 1812, 246-51.
29. Lupardus PJ, Garcia KC. (2008). The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J Mol Biol, 382, 931-41.
30. Martin R, McFarland HF, McFarlin DE. (1992). Immunological aspects of demyelinating diseases. Annu Rev Immunol, 10, 153-87.
31. McGeachy MJ, Chen Y, Tato CM, et al. (2009). The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol, 10, 314-24.
32. McKenzie BS, Kastelein RA, Cua DJ. (2006). Understanding the IL-23-IL-17 immune pathway. Trends Immunol, 27, 17-23.
33. Mills KH. (2008). Induction, function and regulation of IL-17-producing T cells. Eur J Immunol, 38, 2636-49.
34. Moudgil KD, Choubey D. (2011). Cytokines in autoimmunity: Role in induction, regulation, and treatment. J Interferon Cytokine Res, 31, 695-703.
35. Oppmann B, Lesley R, Blom B, et al. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13, 715-25.
36. Sospedra M, Martin R. (2005). Immunology of multiple sclerosis. Annu Rev Immunol, 23, 683-747.
37. Stojanovic I, Cvjeticanin T, Lazaroski S, et al. (2009). Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology, 126, 74-83.
38. Stritesky GL, Yeh N, Kaplan MH. (2008). IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol, 181, 5948-55.
39. Tang C, Chen S, Qian H, Huang W. (2012). Interleukin-23: As a drug target for autoimmune inflammatory diseases. Immunology, 135, 112-24.
40. Vaknin-Dembinsky A, Murugaiyan G, Hafler DA, et al. (2008). Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J Neuroimmunol, 195, 140-5.
41. Weiner HL. (2004). Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol, 61, 1613-15.
42. Wen SR, Liu GJ, Feng RN, et al. (2012). Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol, 244, 94-6.